Hydralazine 50mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hydralazine 50mg tablets

alliance healthcare (distribution) ltd - hydralazine hydrochloride - oral tablet - 50mg

Hydralazine 50mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hydralazine 50mg tablets

phoenix healthcare distribution ltd - hydralazine hydrochloride - oral tablet - 50mg

Hydralazine 50mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hydralazine 50mg tablets

almus pharmaceuticals ltd - hydralazine hydrochloride - oral tablet - 50mg

Hydralazine 50mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hydralazine 50mg tablets

morningside healthcare ltd - hydralazine hydrochloride - oral tablet - 50mg

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochloride and isosorbide dinitrate tablet, film coated United States - English - NLM (National Library of Medicine)

isosorbide dinitrate and hydralazine hydrochloride- hydralazine hydrochloride and isosorbide dinitrate tablet, film coated

wilshire pharmaceuticals - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate and hydralazine hydrochloride tablets are indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. there is little experience in patients with nyha class iv heart failure. isosorbide dinitrate and hydralazine hydrochloride tablets are contraindicated in patients who are allergic to organic nitrates. do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)] . do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. risk summary there are no data on isosorbide

MINT-HYDRALAZINE TABLET Canada - English - Health Canada

mint-hydralazine tablet

mint pharmaceuticals inc - hydralazine hydrochloride - tablet - 50mg - hydralazine hydrochloride 50mg - direct vasodilators

HYDRALAZINE TABLET Canada - English - Health Canada

hydralazine tablet

sanis health inc - hydralazine hydrochloride - tablet - 50mg - hydralazine hydrochloride 50mg

HYDRALAZINE HYDROCHLORIDE- hydralazine hydrochloride tablet United States - English - NLM (National Library of Medicine)

hydralazine hydrochloride- hydralazine hydrochloride tablet

glenmark pharmaceuticals inc., usa - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.